Last updated: September 26, 2023
Sponsor: Beijing Tiantan Hospital
Overall Status: Active - Not Recruiting
Phase
N/A
Condition
Stroke
Blood Clots
Thrombosis
Treatment
LF-rTMS
Clinical Study ID
NCT06064734
HX-A-2023001
Ages 18-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age 18-80 years, gender is not limited;
- Acute ischemic stroke of anterior circulation was diagnosed clinically
- mRS 0-1 score before onset;
- 6 ≤ NIHSS ≤25 at randomization;
- Within 48 hours of stroke onset;
- No thrombolysis therapy or thrombectomy is planned;
- Obtain informed consent signed by the patient himself or by his legal authorizedrepresentative.
Exclusion
Exclusion Criteria:
- TMS contraindications include metallic foreign bodies in the head, pacemaker,implantable drug pumps, cochlear implants, etc.
- Epilepsy or history of epilepsy, intracranial hypertension, tumor and other seriousneurological disorders;
- Midline displacement and brain parenchymal mass effect seen in head CT and otherimages;
- Head CT or MRI showed bilateral acute cerebral infarction and involved insularinfarction;
- Evidence of acute intracranial hemorrhage;
- A history of congenital or acquired hemorrhagic disease, coagulation factordeficiency, or thrombocytopenia disease;
- After blood pressure control, the systolic blood pressure was still ≥180 mmHg or thediastolic blood pressure was ≥110 mmHg;
- Known recent or current serum creatinine exceeding 1.5 times the upper limit of normalor estimated glomerular filtration rate (EGFR) < 60 mL/min;
- Patients during pregnancy or lactation and within 90 days of planned pregnancy;
- Patients with severe mental disorders or dementia who can not cooperate with informedconsent and follow-up;
- Patients with malignancy or severe systemic disease and expected survival of less than 90 days;
- Participants in other clinical intervention studies within 30 days beforerandomization or who were participating in other clinical intervention studies.
Study Design
Total Participants: 60
Treatment Group(s): 1
Primary Treatment: LF-rTMS
Phase:
Study Start date:
October 28, 2023
Estimated Completion Date:
October 30, 2024
Study Description
Connect with a study center
Beijing Tian tan Hospital
Beijing, Beijing 100070
ChinaSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.